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HPV Vaccination in Japan 
The Continuing Debate and Global Impacts 
Rose Wilson, Pauline Paterson, Jeremy Chiu, William Schulz, Heidi Larson1 
 
Introduction 
 
In June 2013, the Japanese Ministry of Health, Labour, and Welfare (MHLW) suspended its 
active recommendation of the human papillomavirus (HPV) vaccination after a small 
number of highly publicized alleged adverse events stoked public fears about the vaccine’s 
safety.2 While the MHLW continues to provide the HPV vaccination for those who request it 
through the National Immunization Programme (NIP), as of mid-April, the suspension of 
the HPV vaccination recommendation continues.  
 
Since the release of our CSIS report The HPV Vaccination in Japan: Issues and Options3 in 
May 2014, anti-vaccine groups have strengthened their control of the narrative surrounding 
the HPV vaccine, intensified their activities, and continued to capture media and public 
attention. The medical community has split as prominent personalities have come forward 
to support claims of adverse effects linked to the HPV vaccine even in the absence of any 
evidence of association. Countermeasures by the MHLW, medical professional groups, and 
others have been comparatively weak and, it appears, ineffectual. It remains unclear how 
and when this increasingly complicated and difficult situation will be resolved.  
 
In this paper, we outline major events with regards to the HPV vaccine controversy in Japan 
since May 2014, highlighting long-term implications of the rapid drop in vaccination 
coverage and recommending how to best move forward. There are also two addendums 
that explore global perspectives on the current situation in Japan and examine examples of 
how other countries have dealt with concerns and opposition to the HPV vaccine. 
 
 
 
1 Rose Wilson is a graduate student, Pauline Paterson a research fellow, Jeremy Chiu a research intern, William 
Schulz a researcher, and Heidi Larson a senior lecturer in the Department of Infectious Disease Epidemiology at 
the London School of Hygiene & Tropical Medicine in London, England. 
2 Heidi Larson et al., “Tracking the global spread of vaccine sentiments: The global response to Japan’s 
suspension of its HPV vaccine recommendation,” Human Vaccines & Immunotherapeutics 9, no. 10 (2014): 1–8.  
3 Rose Wilson, Pauline Paterson, and Heidi Larson, The HPV Vaccination in Japan: Issues and Options 
(Washington, DC: CSIS, May 2014), http://csis.org/files/publication/140514_Wilson_HPVVaccination_Web.pdf. 
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Update on Japan’s HPV Situation since June 2014 
 
Medical Schism 
 
The safety of the HPV vaccine remains a subject of intense controversy and debate in Japan, 
despite global scientific evidence pointing to the vaccine’s safety. Conflicting views have 
proliferated within the medical profession in Japan, as a growing number of physicians 
have spoken publicly in support of claims that the HPV vaccine may lead to adverse events. 
In 2013, Sotaro Sato, a Japanese internist and cardiologist, was widely quoted on anti-
vaccine sites, reporting on the side effects perceived to be caused by the HPV vaccine.4 In 
2014 Kusuki Nishioka, a professor of medicine and director and chairman of the Institute of 
Medical Science, Tokyo Medical University, emerged as a new “expert” claiming a causal 
link between the HPV vaccine and pain symptoms experienced by young women. Nishioka 
spoke at an international rheumatology conference in Moscow on June 5, 2014, with a 
presentation titled “HPV Vaccination Associated with Neuropathic Syndrome (HANS): A 
novel disease entity associated with HPV Vaccination.”5  
 
The Danish website HPV Vaccine Info reported that Nishioka subsequently presented at a 
symposium at Tokyo Medical University on July 27, 2014, titled “What we found in the HPV 
scandal—The problem of medical ethics and education.”6 The conference aimed to 
“consider the actualities and issues of pharmacovigilance in Japan through the scourge of 
HPV (cervical cancer) vaccine injuries.” Cohosts included Medwatcher Japan (a 
nongovernmental organization, NGO, that monitors and seeks to prevent drug-induced 
“disasters”) and The Informed Prescriber (a magazine published by a nonprofit drug 
treatment study group),7 with support from the Japanese Society for 
Pharmacoepidemiology Task Force and DIPEx-Japan (a discussion forum for diseases, 
diagnoses, and side effects).8  
 
In October 2014, other academics became involved in the controversy with the publication 
of an article by Tomoaki Kinoshita et al. that concluded, “Immunization with HPV vaccines 
may secondarily induce sympathetically mediated disorders, including CRPS-I [chronic 
regional pain syndrome type 1], OH [orthostatic hypotension] and POTS [postural 
orthostatic tachycardia syndrome].” The article went on to emphasize that these “disorders 
have not been reported in foreign cohort studies of human HPV vaccines and it thus 
4 “SaneVax Reports on Japan’s Struggle with HPV Vaccination Injuries,” Age of Autism, August 26, 2013, 
http://www.ageofautism.com/2013/08/sanevax-reports-on-japans-struggle-with-hpv-vaccination-injuries.html. 
5 Forum of the University Science, “Program,” June 5, 2014, http://forum-uniscience.ru/en/programma/june-5-
2014/.  
6 “Japansk organisation afslører interessekonklikter,” HPV Vaccine Info, August 7, 2014, http://hpv-vaccine-
info.org/japansk-organisation-afslorer-interessekonklikter/.  
7 Yakugai Ombudsperson “Medwatcher Japan,” Symposium: Consideration of pharmacovigilance—Lessons 
learned from the adverse effect of HPV vaccination,” July 27, 2014, http://www.yakugai.gr.jp/en/topics/ 
topic.php?id=873. 
8 Database of Independent Patient Experience, “DIPEX Japan,” 2015, http://www.dipex-j.org/.  
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 remains unclear why Japanese girls are more frequently involved. It is unlikely that the 
Japanese environment plays a role in the pathogenesis of this disorder.”9  
The authors called for further research on the alleged HPV vaccine side effects, reinforcing 
public concerns. On December 10, 2014, Nishioka presented at a symposium held by the 
Japan Medical Association and the Japanese Association of Medical Sciences, arguing that 
the HPV vaccine should be promoted only after issues regarding the vaccine’s safety are 
firmly settled. This evolving schism within the medical community has continued, with 
many other medical professionals openly supporting HPV vaccine uptake (such as Ryo 
Konno, Japanese Expert Board for the Eradication of Cervical Cancer). On March 30, 2015, 
over 200 medical professionals also took action by signing a statement requesting Japanese 
media to have balanced coverage on HPV vaccination. More than 250 members of the Japan 
Pediatric Society have called upon the government to reinstitute an active recommendation 
for HPV vaccination. 
MHLW Response 
 
In January 2014, a panel of experts within the MHLW ruled out the possibility that changes 
within the immune system or central nervous system caused adverse events following HPV 
vaccination.10 Subsequently, on September 16, 2014, the online newspaper Asahi Shimbun 
reported that following the MHLW statements, Kusuki Nishioka and six other medical 
experts had studied the cases of 2,500 women who complained about health problems after 
receiving the HPV vaccine. Directly contradicting the MHLW, Nishioka and others 
announced at a news conference in Nagano on September 13, 2014, that the side effects are 
caused by a dysfunction within the central nervous system.11 
 
According to the Asahi Shimbun and the Japan News Network,12 the MHLW planned to 
follow up on the approximately 2,500 reported cases of HPV-related side effects and set up a 
system to treat 176 young women who complained about widespread pain and mobility 
disorders that supposedly resulted from the vaccine. While the MHLW’s plan to treat 
women suffering from pain and mobility disorders may be interpreted as a positive gesture 
to appease an anxious public, it risks misinterpretation as an admission that the vaccine did 
in fact cause adverse effects. 
 
9 Tomoaki Kinoshita et al., “Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following 
immunization with the human papillomavirus vaccine,” Internal Medicine 53, no. 13 (2014): 2185–200. 
10 Yakugai Ombudsperson “Medwatcher Japan,” “Regarding the MHLW councils on cervical cancer vaccines 
(HPV vaccines) held on January 20th, 2014,” January 22, 2014, http://www.yakugai.gr.jp/en/topics/ 
topic.php?id=856. 
11 Tomoko Saito, “Researchers: Cervical cancer vaccination linked to symptoms affecting nervous system,” Asahi 
Shimbun, September 16, 2014, http://ajw.asahi.com/article/behind_news/social_affairs/AJ201409160043. 
12 “子宮頸がんワクチンで副反応、製薬会社２社に救済求める,” Japan News Network, 2015. 
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Impacts on the Public  
 
Over the last year, controversy within the Japanese medical and political arenas over the 
HPV vaccine has touched the public at large. Through social media and highly publicized 
events, anti-vaccine groups have gained control of the narrative surrounding the HPV 
vaccine. The reported adverse events following immunization (AEFI) are now established 
“facts” in the eyes of the media and members of the public exposed to unscientific, 
sensationalist reporting. 
Throughout 2013 and 2014, YouTube videos depicting Japanese girls suffering from seizures 
and walking disturbances were common on Japanese social media sites. The Japan National 
Cervical Cancer Vaccine Victim Liaison Committee also posted a disturbing YouTube video 
on its website on November 25, 2014, depicting a Colombian teenage girl suffering from 
walking disturbances.13 
 
The Japan National Cervical Cancer Vaccine Victim Liaison Committee has also staged 
public demonstrations. On March 31, 2015, a protest was held outside MSD (Merck Group) 
and GlaxoSmithKline headquarters in Tokyo, at which the Japan National Cervical Cancer 
Vaccine Victim Liaison Committee submitted its demands to the two companies, calling for 
a halt to HPV vaccination and compensation to be paid to “victims.” The protests were 
broadcast live on TV and online by most major news channels, including Nippon Network 
News,14 All-Nippon News Network,15 and Fuji News Network.16 The anti-vaccination group 
held a press conference and then moved to the MHLW, where the members again 
submitted their demands. Finally, they spoke to an audience with elected officials. These 
events were planned well in advance and advertised through individual blogs and social 
media sites.17 
13 “全世界で被害が出ています!!,” National Cervical Cancer Vaccine Victim Liaison Committee, November 25, 2014, 
http://hpvv-danger.jp/archives/653. 
14 “中高生ら 子宮頸がんワクチンの被害訴え,” Nippon Network News, 2015. 
15 “「子宮頸がんワクチン」”副作用”被害で2500件報告,” All-Nippon News Network, 2015. 
16 “「子宮頸がんワクチン被害者団体、製薬会社に初めて要求書提出,” Fuji News Network, 2015.  
17 “みかりんのささやき～子宮頸がんワクチン被害のブログ～,” Ameba, March 30, 2015, http://ameblo.jp/3fujiko/ 
entry-12007957544.html. 
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National Cervical Cancer Vaccine Victim Liaison Committee: Teenage women and parents complain about side 
effects after receiving cervical cancer vaccine. 
On April 25, 2015, the National Cervical Cancer Vaccine Victim Liaison Committee will hold 
a national meeting titled “Vaccine Talk 2015” in the Chiyoda ward of Tokyo. The gathering 
will focus on expanding its network of support for “victims” of the HPV vaccine. Invited 
speakers include professors from the University School of Medicine, members of the Saku 
Health and Welfare Office, and members of the editorial boards of online newspapers.18 
See Table 1 for a timeline of major events relating to the HPV vaccine in Japan. 
18 “2015ワクチントーク全国集会開催のお知らせとプライベート・コメントの募集(しめきりは3月29日です,” 
ConsumerNet.Jp, February 13, 2015, http://consumernet.jp/?p=1659. 
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Table 1: Major Events in Japan Related to the HPV Vaccine (2009–2015) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Implications of Policy Choices 
 
Eroded Public Trust 
The MHLW’s suspension of active recommendation of HPV vaccination in Japan has 
negatively impacted public trust in the vaccine. The lack of information regarding the 
reported AEFI, combined with the lack of a clear decision by the Japanese government to 
reinstate active promotion of HPV vaccination, created an information void. Anti-
March 2010 
After HPV vaccination, three 
girls complain of complex 
regional pain syndrome (CRPS) 
and nine from chronic pain. 
April 2010 
126 of 1,747 local governments 
were providing funding for the 
HPV vaccine. 
October 2010 
Central and all local governments 
launch a temporary funding 
program. 
March 8, 2013 
Asahi newspaper press report of 
50 girls suffering from CRPS and 
100 absent from school after 
receiving HPV vaccine. 
March 10, 2013 
Adverse events reported on TV 
news. 
March 25, 2013 
Press conference by “victim” 
group showing videos of girls 
suffering from walking 
disturbances and seizures, which 
was also posted on YouTube. 
April 1, 2013 
HPV vaccine included in 
National Immunization Program 
(NIP). Optional and given for 
free. 
April 13, 2013 
Suginami local government 
announces its annual budget 
compensation for parents 
claiming their daughters had 
suspected CRPS following HPV 
vaccination. Case reported at 
local assembly meeting. 
May 19, 2013 
Another press conference by 
“victim” group. 
June 13, 2013 
World Health Organization 
(WHO) Global Advisory 
Committee on Vaccine Safety 
report released stating HPV 
vaccine is safe. Not reported in 
Japanese media. 
June 14, 2013 
Second joint meeting of Vaccine 
Adverse Reactions Review 
Committee (VARRC). MHLW 
decided to temporarily suspend 
recommendation of HPV 
vaccine. 
October 2014 
National Cervical Cancer Vaccine 
Victim Liaison Committee opens 
branch in Osaka. 
December 10, 2014 
Symposium held by Japan 
Medical Association and 
Japanese Association of Medical 
Sciences. Concludes that HPV 
vaccines should be promoted 
only after issues regarding 
vaccine safety are settled. 
March 31, 2015 
Anti-vaccination groups hold 
protest outside MSD and GSK, 
which is broadcast live on TV 
and online news channels. They 
then hold press conference and 
visit MHLW to submit their 
demands. 
April 25, 2015 
National Vaccine Talk in Tokyo 
Chiyoda ward organized by anti-
vaccination groups. Theme is 
cervical cancer vaccine victims 
and reports of adverse events, 
with aim of expanding network of 
support for “victims.” 
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 vaccination individuals subsequently filled this void, allowing rumors to proliferate and 
spread. 
Other MHLW actions have fueled public skepticism, aggravated anti-HPV vaccine 
sentiment, and amplified fears of AEFI. When a local government authority agreed to 
provide compensation, anti-vaccine activists saw this as an admission of guilt and 
confirmation of a causal link between the vaccine and pain symptoms. By early 2015, the 
cumulative impact was a drop in HPV vaccine uptake from over 70 percent to under 5 
percent for adolescent girls.19 
The trigger for increased media coverage in Japan was the publicity gained by anti-
vaccination groups, one of which is headed by politician Toshie Ikeda, who is highly active 
on Facebook and Twitter and an influential leader in the narrative on anti-vaccine 
sentiment.20 Anti-vaccination groups continue to grow: on October 4, 2014, the Japan Times 
reported that the National Cervical Cancer Vaccine Victim Liaison Committee, which 
currently has 287 members and operates six branches across the country, including 
Hokkaido and Kumamoto, was poised to open a new branch in Osaka.  
 
In Japan, the absence of an effective media watchdog and relatively lax libel laws mean that 
newspapers, news programs, social networks, and victim support groups can freely 
publish—with little if any accountability—unverified stories and videos of girls who claim 
to suffer from adverse events following HPV vaccination.21  
 
The Cost of Not Recommending the HPV Vaccine 
 
Japan’s suspension of proactive recommendation of the HPV vaccine continues to baffle the 
global scientific community.22 The long-term costs of not recommending the HPV vaccine 
are considerable, but the impact in terms of cervical cancer deaths and morbidity may not 
be seen for decades. It has been suggested that the number of cervical cancer cases could be 
reduced by 73 percent if all 12-year-old girls in Japan were vaccinated.23  
 
Not actively promoting HPV vaccination is putting the Japanese population at long-term 
unnecessary risk. It is estimated that 67.1 percent of cervical cancers in Japan are related to 
HPV types 16 and 18.24 Cervical cancer is the second-most-common female cancer in 
19 “Suspension of Government Support for the HPV Vaccine,” BBC, February 8 2015, http://www.bbc.co.uk/ 
programmes/p02ht8wt. 
20 Wilson, Paterson, and Larson, The HPV Vaccination in Japan: Issues and Options. 
21 Ibid. 
22 Stuart Gilmour et al., “HPV Vaccination Programme in Japan,” The Lancet 382 (2013): 768; Norma Erikson, 
“Japan and the HPV Vaccine Controversy,” SaneVax Inc., April 8, 2014, http://sanevax.org/japan-hpv-vaccine-
controversy/. 
23 Ryo Konno et al., “Cervical Cancer Working Group Report,” Japanese Journal of Clinical Oncology 40 (2010) 
Supplement 1: i44–i50. 
24 Ibid. 
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women aged 15 to 44 years in Japan,25 and the rate of Pap tests is low, at around 25.4 
percent.26 Oropharyngeal cancers are on the rise,27 and over the past 10 years, and nearly 
6,000 cases of genital warts have been reported annually on average.28 Not actively 
promoting HPV vaccination, and the associated media hype surrounding vaccine side 
effects, has the additional risk of reducing uptake of other essential immunizations.  
 
Recommendations  
 
1. Reinstate an active government recommendation of HPV vaccination. To dispel fear 
and misinformation, it is first essential that high-level Japanese political leadership restores 
an active recommendation for HPV vaccination. This should be supported by evidence 
including statistics on the vaccine’s safety and successful implementation and high uptake 
rates of the vaccine in other countries. This process should entail continuous and open 
engagement with the media and key stakeholders such as the MHLW. Where possible, 
documenting the public health impacts of the suspended recommendation through 
monitoring HPV infection rates and cervical cancer will also be an important advocacy tool. 
A cancer registration and surveillance system to collect morbidity and mortality data has 
also been recommended to monitor the positive success and impacts of HPV vaccination 
uptake.29  
 
2. Support Japanese production of the HPV vaccine. Takeda Pharmaceutical Company 
(the largest pharmaceutical company in Asia) has announced that it transferred its license 
agreement with the Japan Health Sciences Foundation for worldwide patent rights of an 
HPV vaccine to the Chemo-Sero-Therapeutic Research Institute (Kaketsuken) in Japan on 
March 10, 2015.30 An efficacious Japanese-manufactured HPV vaccine could increase trust 
in the vaccine. 
 
3. Listen more carefully to the public at large. Politicians and those within the MHLW 
are well advised to more carefully listen to the public. Many within the scientific 
community have suggested that AEFI following HPV vaccination are psychogenic.31 
25 HPV Information Centre, “Human Papillomavirus and Related Diseases Report: Japan,” March 20, 2015, 
http://www.hpvcentre.net/statistics/reports/JPN.pdf. 
26 Takahiro Tabuchi et al., “Does Removal of Out-of-pocket Costs for Cervical and Breast Cancer Screening Work? 
A Quasi-experimental Study to Evaluate the Impact on Attendance, Attendance Inequality and Average Cost per 
Uptake of a Japanese Government Intervention,” International Journal of Cancer 133, no. 4 (2013): 972–83. 
27 D. Forman et al., “Global Burden of Human Papillomavirus and Related Diseases,” Vaccine 30 (2012) 
Supplement 5: F12–23. 
28 Hirokazu Yoshikawa et al., “Efficacy of Quadrivalent Human Papillomavirus (types 6, 11, 16 and 18) Vaccine 
(GARDASIL) in Japanese Women Aged 18–26 Years,” Cancer Science 104, no. 4 (2013): 465–72. 
29 Heidi J. Larson, Pauline Brocard, and Geoffrey Garnett, “The India HPV-Vaccine Suspension,” The Lancet 376 
(2010): 572–73.  
30 “Takeda Announces Transfer of License Agreement for Human Papillomavirus (HPV) Vaccine to Kaketsuken,” 
PipelineReview.com (La Merie Publishing), March 10, 2015, http://pipelinereview.com/index.php/ 
2015031057121/More-News/Takeda-Announces-Transfer-of-License-Agreement-for-Human-Papillomavirus-HPV-
Vaccine-to-Kaketsuken.html. 
31 J. Paul Buttery et al., “Mass Psychogenic Response to Human Papillomavirus Vaccination,” Medical Journal of 
Australia 189, no. 5 (2008): 261–62. 
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 Members of the public may perceive this label (and the term “mass hysteria”) as 
patronizing and dismissive of real concerns and actual physical suffering.32  
In cases of mass psychogenic illness following immunization, a crisis of confidence can 
erupt around a vaccine and manifest itself in frightening physical symptoms. Claims of 
psychogenic adverse reactions should not be ignored or dismissed as specious; shutting out 
dissenters only creates fodder for less-informed groups, as anti-vaccine sentiment, 
misinformation, and possibly even psychogenic adverse reactions themselves can spread 
over the Internet and social media worldwide. 
4. De-stigmatize HPV. Perception of disease risk has a large influence on vaccine 
acceptance. In some cases, cultural and social mores, such as those pertaining to sexual 
behavior, influence vaccine acceptance. In the case of HPV vaccination, social beliefs about 
sexual behavior may overshadow appreciation of the true health risks of the virus.33 HPV 
transmission does occur mainly through skin-to-skin mucosa contact during sex, but there 
is some evidence to suggest that HPV can be transmitted through nonsexual contact.34 This 
fact, as well as education surrounding the other cancers that HPV can cause, could be used 
in promotional materials to alleviate stigma surrounding the vaccine. 
Conclusion 
In the past year, the situation in Japan vis-à-vis HPV vaccine policy has become far more 
complicated and difficult to unwind. Anti-vaccine interests have strengthened their control 
over messaging and the media airwaves, intensified political pressures, and contributed to 
further erosion of public trust and confidence. An emerging group of scientists and medical 
researchers are joining the anti-HPV vaccine camp, claiming a causal link between the HPV 
vaccine and pain syndrome without evidence to support their assertions. Serious spillover 
effects persist, both within Japan itself and in other countries where there is active debate 
over the scientific merits of the vaccine. Ineffective action and a conspicuous lack of high-
level political leadership from the Japanese government only invites more, not less, intense 
action by anti-vaccine interests. The acute problem seen in Japan is rooted in society and 
politics and will require political leadership by senior members of the current 
administration, particularly within the context of Prime Minister Abe’s “womenomics” 
initiative. Leadership, science, and sustained public health efforts will all be essential in 
finding a lasting resolution. 
  
32 C. John Clements, “Mass Psychogenic Illness after Vaccination,” Drug Safety 26, no. 9 (2003): 599–604. 
33  Heidi J. Larson, “Commentary: The uptake of human papillomavirus vaccination: The power of belief,” 
International Journal of Epidemiology 42, no. 3 (2013): 908–10. 
34 Eric J. Ryndock and Craig Meyers, “A risk for non-sexual transmission of human papillomavirus?,” Expert 
Review of Anti-infective Therapy 12, no. 10 (2014): 1165–70. 
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Addendum 1: Update of International Perception of the HPV 
Controversy in Japan 
 
Anti-HPV-vaccination groups worldwide have applauded the MHLW’s decision to suspend 
the recommendation of the HPV vaccination, as concerns surrounding the vaccine’s safety 
have surfaced in many countries. This addendum focuses on how other countries have 
been influenced by the situation in Japan.  
Denmark 
A documentary titled “De Vaccinerede Piger” 
(“The Vaccinated Girls”) was televised in 
Denmark in March 2015. In the documentary, 
several Japanese doctors relayed fears that the 
HPV vaccine causes severe side effects.35 The 
film focused on statements from Kusuki 
Nishioka, who claimed that Japan suspended its 
HPV recommendation in response to these 
adverse effects. The documentary featured the 
stories of 47 Japanese girls who believed they 
became ill after receiving the HPV vaccine. 
Danish support for Japan’s suspension of its HPV 
vaccine recommendation could have dangerous 
consequences for vaccine uptake in Denmark. 
According to Zeraiq et al., who studied attitudes 
and knowledge toward HPV vaccination among Arab mothers and their daughters in 
Denmark, there is already a vaccination knowledge gap between generations.36, 37 
Anti-vaccination websites such as SaneVax have been quick to republish such stories. 
SaneVax (which originated in the United States) published a letter from parents in Denmark 
35 Nicolaj Albrectsen, Michael Bech, and Signe Daugbjerg, “Piger bliver syge: I Japan anbefaler de ikke længere 
HPV-vaccinen,” TV2, March 27, 2015, http://nyhederne.tv2.dk/samfund/2015-03-27-piger-bliver-syge-i-japan-
anbefaler-de-ikke-laengere-hpv-vaccinen. 
36 Lina Zeraiq, Dorthe Nielsen, and Morten Sodemann, “Attitudes towards human papillomavirus vaccination 
among Arab ethnic minority in Denmark: A qualitative study,” Scandinavian Journal of Public Health, March 9, 
2015 [E-pub ahead of print]. 
37 They found that mothers turned to Arabic television channels as a source of health information, whereas 
daughters used the Internet and Western television channels, and that mothers who do not speak Danish learn 
about the HPV vaccine from their daughters. If their daughters watch a documentary such as “De Vaccinerede 
Piger,” it is likely that the information would be passed on to their mothers. Due to language barriers, many 
mothers are unable to read information provided by the Ministry of Health, and a very unbalanced view of the 
vaccine is formed from readily available anti-vaccine media. These sentiments can be exacerbated by the 
mothers’ social networks, which largely comprise other Arabic-speaking mothers and often have a fear-inducing 
impact on the mothers’ perception of the HPV vaccine. This is especially worrying as the study also found that a 
key motivator for the daughters’ acceptance of the vaccine stemmed from their mothers’ approval. 
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 that refers to Japan’s suspension of its HPV vaccine recommendation; India’s prohibition of 
the vaccine following deaths in clinical studies, as well as a potential lawsuit brought 
against Merck; 1,200 health professionals in France refusing to vaccinate against HPV; and 
France and Spain initiating action against the manufacturer.38 According to SaneVax, the 
letter will be sent to the Danish Parliament, Danish health authorities, and the Danish press; 
shared with the international press in United States, England, France, Spain, India, and 
Japan; circulated in various medical magazines; and posted to Facebook. 
Despite pressure from anti-vaccination groups, the Danish Health and Medicines Authority 
(DHMA) has been monitoring and evaluating reports of suspected adverse reactions 
associated with the HPV vaccination since its introduction in 2009,39 and in September 2014 
the DHMA stated, “[T]he Danish Health and Medicines Authority still assesses that the 
benefits of the HPV vaccine outweigh the possible risks.”40 Vaccination uptake remains high 
for girls, at around 70 percent.41 
New Zealand 
New Zealand approved the use of HPV vaccination for both females and males in 200642 
and provides it for free to girls under the age of 20, mainly through a school-based 
vaccination program.43  
Coverage is currently low for girls at 52.6 percent for all three doses.44 One of the reasons 
for this is a fear among parents that giving adolescents the vaccine could encourage sexual 
debut at a young age.45 The group Family First NZ claims that parents in New Zealand are 
rightly rejecting the pressure to have their children vaccinated against a “consequence of 
behavior,” not an infectious disease. The group cites various sources of incidence data on 
HPV AEFI, namely reports by the Centers for Disease Control and Prevention (CDC) and 
BMJ. Family First NZ cited Japan’s decision to suspend its HPV vaccine recommendation in 
38 SaneVax, “The HPV Vaccine Scandal in Denmark,” August 17, 2014, http://sanevax.org/hpv-vaccine-scandal-in-
denmark/. 
39 Danish Health and Medicines Authority, “Danish Pharmacovigilance Update, May 2014,” volume 5, July 14, 
2014, https://sundhedsstyrelsen.dk/en/news/2014/danish-pharmacovigilance-update-may-2014. 
40 Danish Health and Medicines Authority, “Danish Pharmacovigilance Update, September 2014,” volume 5, 
October 17, 2014, http://sundhedsstyrelsen.dk/en/news/2014/danish-pharmacovigilance-update,-september-2014.  
41 Zeraiq , Nielsen, and Sodemann, “Attitudes towards human papillomavirus vaccination among Arab ethnic 
minority in Denmark.” 
42 The New Zealand HPV Project, “About HPV Vaccine,” http://www.hpv.org.nz/hpv-vaccine/about-hpv-vaccine. 
43 Ministry of Health NZ, “HPV immunisation programme,” http://www.health.govt.nz/our-work/preventative-
health-wellness/immunisation/hpv-immunisation-programme. 
44 Ministry of Health NZ, “HPV Immunisation Coverage by Ethnicity, Vaccination and Eligible Birth Cohort—All 
DHBs [District health boards],” March 7, 2014, http://www.health.govt.nz/system/files/documents/pages/ 
hpv_immunisation_coverage_by_ethnicity_vaccination_and_eligibile_birth_cohort-feb2014.pdf. 
45 “Herald on Sunday editorial: Why do Pakeha spurn HPV vaccine?,” The New Zealand Herald, March 15, 2015, 
http://www.nzherald.co.nz/opinion/news/article.cfm?c_id=466&objectid=11417400. 
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2013 and mentioned Sataro Sato, the Japanese internist and cardiologist who dominated the 
Japanese scientific narrative in the media in 2013 and 2014.46 
Colombia 
Japanese online discussions have referred to a cluster of reported adverse events following 
HPV immunization in Colombia as proof of other AEFIs. 
Colombia has provided the HPV vaccine for free since September 2012. Although some 
religious groups feared that the vaccine would cause promiscuity, by 2013 average uptake 
had reached around 70–80 percent for adolescent girls. 
However, on May 28, 2014, the first suspected AEFI was reported in the small town of El 
Carmen de Bolívar. By June 3, 2014, more girls had reported side effects from the vaccine47 
that were remarkably similar to the symptoms reported in Japan, including weakness in the 
legs and fainting. This was widely reported by major Colombian news outlets48, 49 and an 
increase in reported side effects followed. However, very few cases of AEFI were reported 
during the school holiday, from mid-June to mid-July.  
In August 2014, the government paid for the affected girls to receive specialized treatment. 
Reports peaked at the end of August when the governor of El Carmen de Bolívar met with 
officials from the National Institutes of Health (NIH) and a member of Parliament in El 
Carmen de Bolívar. Forty-five AEFI were reported in one day, with lawyers encouraging 
“victims” to bring their cases forward.  
NIH carried out a thorough investigation,50 considering claims that lead poisoning or even 
the use of Ouija boards had caused the symptoms. They surveyed around 400 girls who had 
reported symptoms but had not visited a doctor, finding that 20 percent of girls had not 
been vaccinated in the first place. There was no direct or indirect evidence linking the 
vaccine and the reported symptoms, and most girls were discharged from the hospital 
within an hour and without any abnormal findings.51 However, when the president sought 
to alleviate concerns by dismissing the reported AEFI as a “phenomenon of collective 
46 Family First NZ, “Parents Right to Question HPV Vaccine,” March 15, 2015, https://www.familyfirst.org.nz/ 
2015/03/parents-right-to-question-hpv-vaccine/. 
47 Paula Carrillo, “Mystery illness plagues girls in Colombia,” Agence France-Presse, September 18, 2014, 
http://news.yahoo.com/mystery-illness-plagues-girls-colombia-052825963.html.  
48 Benjamin Radford, “Colombian Girls Blame Vaccine for Mysterious Symptoms,” Discovery News, September 
24, 2014, http://news.discovery.com/human/psychology/colombian-girls-blame-vaccine-for-mysterious-
symptoms-140924.htm. 
49 “Hundreds of teenage girls in Colombia struck by mystery illness,” Associated Press, August 27, 2014, 
http://globalnews.ca/news/1530883/hundreds-of-teenage-girls-in-colombia-struck-by-mystery-illness/. 
50 Christoffer Frendesen, “Government investigates mystery illness affecting teen girls in Colombia’s north,” 
Columbia Reports, August 28, 2014, http://colombiareports.co/hospitalization-200-girls-northern-colombia-
teenage-generates-concern-vaccine/. 
51 MinSalud, “Vacuna contra VPH no tiene relación con casos de niñas de Carmen de Bolívar,” Press bulletin No. 
234, August 28, 2014, http://www.minsalud.gov.co/Paginas/Vacuna-contra-VPH-no-tiene-relaci%C3%B3n-con-
casos-de-ni%C3%B1as-de-Carmen-de-Bol%C3%ADvar.aspx. 
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 suggestion,” this stirred charges that the government was disregarding the “victims’” 
experiences.52 Forty sufferers took to social media, posting videos of their symptoms, 
sparking a media sensation53 and leading to a string of public protests.54 
Colombian and Japanese anti-vaccine groups have used social media in similar ways. Very 
recently, the Colombian government provided Internet access, cheap laptops, and tablets to 
smaller towns; most young people have subsequently been able to access Facebook and 
YouTube, where anti-vaccination content is abundant. Through these new modes of 
communication, transmission of information has changed, with children watching these 
videos online and then relaying the information to their parents.55 
News of these events has quickly spread around the world (Figure 1). On February 27, 2015, 
the National Cervical Cancer Vaccine Victim Liaison Committee (an anti-HPV-vaccination 
group in Japan) posted an article on its Facebook page referring to the situation in 
Colombia. The article includes a quote from Yehuda Shoenfeld, an autoimmune disease 
expert at the University of Tel Aviv, stating that he considered it improbable that the 
symptoms experienced by girls are psychological. Shoenfeld also mentioned that 
“thousands” of women were similarly affected by the vaccine in the United States.56 
Due to these events, as of April 2015, vaccine coverage in Colombia has fallen from around 
80 percent to 20 percent among girls.57 However, reported cases of AEFI from El Carmen de 
Bolívar have greatly decreased, the national vaccine recommendation has not been 
withdrawn, and the vaccine continues to be part of the National Immunization Program 
(NIP).58 
The reduction in reported AEFI could be due to a number of factors. First, Colombian news 
coverage has recently been dominated by an outbreak of Chikungunya, diverting attention 
away from the HPV controversy and possibly reducing the social stimulus that drives mass 
psychogenic illness.59 Second, unlike the case in Japan, the Colombian government (which 
52 Gabrielle Mentjox, “‘Mass hysteria’ probable cause of mystery illness in 100s of Colombia schoolgirls: 
President Santos,” Columbia Reports, September 1, 2014, http://colombiareports.co/mass-hysteria-probable-
cause-mystery-illness-100s-colombia-schoolgirls-president-santos/. 
53 Heidi Larson and Will Schulz, “The State of Vaccine Confidence 2015,” London School of Hygiene and Tropical 
Medicine: The Vaccine Confidence Project, http://www.vaccineconfidence.org/The-State-of-Vaccine-Confidence-
2015.pdf. 
54 Benjamin Radford, “Colombian Girls Blame Vaccine for Mysterious Symptoms,” Discovery News, September 24 
2014, http://news.discovery.com/human/psychology/colombian-girls-blame-vaccine-for-mysterious-symptoms-
140924.htm. 
55 Leonardo Arregoces, London School of Hygiene and Tropical Medicine, e-mail communication, April 9, 2015.  
56 Miguel Jara, “Los daños de la vacuna del papiloma humano NO son sólo psicológicos,” February 22, 2015, 
http://www.migueljara.com/2015/02/22/los-danos-de-la-vacuna-del-papiloma-humano-no-son-solo-psicologicos/.  
57 “Caso de niñas del Carmen de Bolívar desplomó vacunación contra el VPH,” El Tiempo, February 14, 2015, 
http://www.eltiempo.com/estilo-de-vida/salud/vacuna-contra-el-papiloma-humano-cayo-58-puntos-
porcentuales/15246061. 
58 MinSalud, “Programa Ampliado de Inmunizaciones (PAI),” http://www.minsalud.gov.co/salud/ 
publica/Vacunacion/Paginas/pai.aspx. 
59 “Chikungunya infections spread to Colombia,” BBC, September 11, 2014, http://www.bbc.co.uk/news/world-
latin-america-29169337. 
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most Colombians trust) and particularly the Ministry of Health are firmly confident in the 
safety and efficacy of the HPV vaccine.60 Third, various scientific societies locally and 
globally supported the government, actively reminding the public of the dangers of cervical 
cancer.61 Finally, the Catholic church supports vaccination, which proved crucial in 
convincing Colombia’s Catholic populace of the HPV vaccine’s safety. One priest encouraged 
a dialogue between angry parents and the Ministry of Health, which helped parents accept 
that there was no likely link between the vaccine and AEFI.62 
Figure 1. Map showing global transmission of: 1) Information about other countries’ HPV 
situation reported in the Japanese media; and 2) reporting and discussion on the Japanese 
suspension of the HPV vaccine recommendation outside of Japan (January 2014–April 2015) 
 
 
 
Source: Heidi J. Larson et al., “Tracking the global spread of vaccine sentiments: The global response to Japan’s 
suspension of its HPV vaccine recommendation,” Human Vaccines & Immunotherapeutics 9, no. 10 (2014): 1–8. 
 
 
 
60 Larson and Schulz, “The State of Vaccine Confidence 2015.” 
61 MinSalud, “Vacuna contra VPH no tiene relación con casos de niñas de Carmen de Bolívar,” Press bulletin No. 
234, 2014, http://www.minsalud.gov.co/Paginas/Vacuna-contra-VPH-no-tiene-relaci%C3%B3n-con-casos-de-
ni%C3%B1as-de-Carmen-de-Bol%C3%ADvar.aspx. 
62 Leonardo Arregoces, London School of Hygiene and Tropical Medicine, e-mail communication, April 9, 2015. 
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 Addendum 2: Country Case Studies of Relevant HPV 
Vaccination Events 
 
Other countries have also experienced low uptake of the HPV vaccine. This addendum 
explores the reasons contributing to low uptake and how each country has endeavored to 
address the situation. 
France  
In 2013, contradictory reports were released regarding a young woman’s complaint about 
an AEFI in response to the HPV vaccine.63 In September 2014, Henri Joyeux, an oncology 
and surgery specialist from the Faculty of Medicine, Montpellier, published cautionary 
statements regarding an authorization from the Haut Conseil de la Santé Publique (High 
Counsel of Public Health) to administer Gardasil® to girls aged nine and above64 compared 
to the previous established age of 11.65, 66 Joyeux started an online petition with the Institut 
pour la Protection de la Santé Naturelle (IPSN) on September 15, 2014, calling for a stop to 
school-based HPV vaccination.67 As of April 1, 2014, the petition had received 374,093 
signatures. Letters bearing the signatures, many of which came from outside of France, 
were sent to the French president, Ministry of Health, and Ministry of Education on October 
9, 2014.68 
Again, the anti-vaccination site SaneVax has been quick to misreport the situation, stating 
that 1,200 French health professionals are refusing to vaccinate; that the domestic 
manufacturer of the vaccine had threatened to withdraw its production from the country if 
aluminium in vaccines is prohibited; that doctors from La Réunion (a French island in the 
Indian Ocean) have requested a commission to investigate the HPV vaccine and to stop 
vaccination until the results are available; and that France and Spain have taken legal 
63 Laetitia Clavreul and Emeline Cazi, “Des experts font le lien entre Gardasil et sclérose en plaques,” Le Monde, 
November 24, 2013, http://www.lemonde.fr/sante/article/2013/11/24/premiere-plainte-contre-levaccin- 
anticancer-gardasil_3519409_1651302.html; “Santé: Le Vaccine Gardasil Bientôt Visé par Trios Nouvelle 
Plaintes,” Le Parisien, November 24, 2013, http://www.leparisien.fr/laparisienne/sante/sante-le-gardasil-au-
coeur-d-une-plainte-24-11-2013-3344849.php; Sanofi Pasteur MSD, “Sanofi Pasteur MSD Rejects Opinion of 
Regional French Compensation Group in Gardasil Vaccination Claim,” Sanofi Pasteur MSD media statement, 
November 25, 2013, https://www.spmsd.co.uk/upload/public/Files/10/ 
Final%20SPMSD%20Media%20Statement_Gardasil%20FR.pdf.  
64 Breizh-info.com, “Papillomavirus (HPV): Le professeur Henri Joyeux sonne l’alarme,” September 9, 2014, 
http://www.breizh-info.com/16822/sante/papillomavirus-hpv-professeur-henri-joyeux-sonne-lalarme/. 
65 Haut Conseil de la Santé Publique, “Infections à HPV: Nouveau schéma vaccinal du vaccin Gardasil®,” March 
28, 2014, http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=416. 
66 Haut Conseil de la Santé Publique, “Vaccination contre les infections à papillomavirus humains. Données 
actualisées,” July 10, 2014, http://www.hcsp.fr/Explore.cgi/avisrapportsdomaine?clefr=454. 
67 Institut pour la Protection de la Santé Naturelle, “NON à la vaccination massive des enfants contre les 
papillomavirus,” September 25, 2014, http://www.ipsn.eu/actualites/non-a-la-vaccination-massive-des-enfants-
contre-les-papillomavirus/. 
68 Institut pour la Protection de la Santé Naturelle, “Vaccins HPV, les autorités réagissent…,” November 19, 2014, 
http://www.ipsn.eu/actualites/vaccins-hpv-les-autorites-reagissent/. 
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action against the manufacturer. However, the HPV vaccine continues to be administered 
under the NIP and a national recommendation for vaccination stands. 
United States  
On July 30, 2014, a 12-year-old girl died in Wisconsin, just hours after receiving an HPV 
vaccine.69, 70 There was no official government statement regarding the incident until 
October 22, 2014, when local media reported the medical examiner’s findings that the death 
was unrelated to the HPV vaccine.71 Over the following months, other groups moved to 
build a narrative and fill the void of public information: news of the event began to spread 
across the country, to the United Kingdom, and to other anti-vaccination 
communities.72, 73, 74, 75, 76, 77 
After the government statement was issued, many media outlets (with the notable 
exception of anti-vaccination websites) updated their previous reports to publish the 
findings and reduce speculation.78 On December 10, 2014, the Food and Drug 
Administration (FDA) approved Gardasil®-9, a new 9-valent HPV vaccine that covers the 
existing quadrivalent Gardasil® panel of HPV 6, 11, 16, 18, with the addition of other high-
risk (oncogenic) HPV subtypes, namely HPV 31, 33, 45, 52, and 58.79, 80, 81 
69 Myra Sanchick and Ashley Sears, “‘The only thing different about that day was that shot’: Did a trip to the 
doctor kill a healthy 12-year-old girl?,” Fox 6 Now, August 7, 2014, http://fox6now.com/2014/08/07/the-only-thing-
different-about-that-day-was-that-shot-did-a-trip-to-the-doctor-kill-a-healthy-12-year-old-girl/. 
70 Mark Johnson, “A day that started with a routine doctor visit ends in girl’s death,” Journal Sentinel, August 7, 
2014, http://www.jsonline.com/news/health/for-girl-a-day-that-started-with-a-routine-doctors-visit-ended-in-her-
death-b99326702z1-270410121.html. 
71 Karen Herzog, “Medical examiner: Girl’s death not caused by HPV vaccination,” Journal Sentinel, October 22, 
2014, http://www.jsonline.com/news/health/medical-examiner-girls-death-not-caused-by-routine-vaccination-
b99376029z1-280058462.html. 
72 Jessica Jerreat, “‘Did the HPV vaccine kill my daughter’: Mother demands answers after healthy and active 
daughter, 12, collapses and dies after getting vaccine,” Daily Mail, August 8, 2014, 
http://www.dailymail.co.uk/news/article-2720333/Did-HPV-vaccine-kill-daughter-Mother-demands-answers-
healthy-active-daughter-12-collapses-dies-getting-vaccine.html. 
73 Deborah Hastings, “Wisconsin mom: ‘Did HPV vaccine kill my 12-year-old daughter?,’” New York Daily News, 
August 8, 2014, http://www.nydailynews.com/news/national/wisc-mom-hpv-vaccine-killed-12-year-old-girl-
article-1.1897850. 
74 “Family: 12-Year-Old Daughter Died Hours after Getting HPV Vaccine,” CBS Atlanta, August 12, 2014, 
http://atlanta.cbslocal.com/2014/08/12/family-12-year-old-daughter-died-hours-after-getting-hpv-vaccine/. 
75 Health Impact News, “Gardasil Vaccine: One More Girl Dead,” August 11, 2014, 
http://healthimpactnews.com/2014/gardasil-vaccine-one-more-girl-dead/. 
76 SaneVax, “Gardasil Vaccine: One more girl dead,” August 17, 2014, http://sanevax.org/gardasil-vaccine-one-
girl-dead/. 
77 “Healthy 12-Year-Old-Girl Dies after Injected with HPV Vaccine,” Inquisitr News, September 28, 2014, 
http://www.inquisitr.com/1504519/healthy-12-year-old-girl-dies-after-injected-with-hpv-vaccine/. 
78 Myra Sanchick, “Medical Examiner: HPV vaccine did not cause death of 12-year-old Waukesha girl,” Fox 6 
Now, October 22, 2014, http://fox6now.com/2014/10/22/medical-examiner-hpv-vaccine-did-not-cause-death-of-12-
year-old-waukesha-girl/. 
79 Merck, “FDA Approves Merck’s HPV Vaccine, GARDASIL®9, to Prevent Cancers and Other Diseases Caused by 
Nine HPV types—Including Types That Cause about 90% of Cervical Cancer Cases,” December 11, 2014, 
http://www.mercknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-hpv-vaccine-
gardasil9-prevent-cancers-an. 
80 Elmar A. Joura et al., “A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women,” New 
England Journal of Medicine 372 (2015): 711–23. 
16 | WILSON, PATERSON, CHIU, SCHULZ, AND LARSON 
                                                 
 India 
In April 2010, the Indian government suspended a national HPV vaccination demonstration 
project due to pressure from advocacy groups. Public concerns centered around the target 
population, relevance, safety, cost-effectiveness of the vaccine, as well as distrust of the 
pharmaceutical industry.82 Suspension of the demonstration project generated controversy, 
petitions, parliamentary investigations, recommendations and reports,83 and ongoing 
Supreme Court hearings.84, 85, 86 The Parliamentary Standing Committee even asked the 
government to take up the matter with other countries where PATH (Program for 
Appropriate Technology in Health) had assisted in similar demonstration projects, 
including Uganda, Vietnam, and Peru.  
The private health sector has provided the HPV vaccine since mid-2010. In early 2015, the 
National Immunization Technical Advisory Group (NITAG) was invited to evaluate the 
safety and efficacy of the vaccine for its introduction into the Indian NIP. However, the 
earliest projected implementation will be in 2016.87 
United Kingdom 
Following reports of a young girl’s death after receiving an HPV vaccination, the UK 
government opened an investigation and issued a response within 24 hours, clarifying that 
the vaccine had not caused the girl’s death.88 
Since 2013, there have been calls to expand HPV vaccination to boys.89, 90 In November 2014, 
the Joint Commission on Vaccination and Immunization resolved that it would be more 
81 National Cancer Institute, “Gardasil 9 Vaccine Protects against Additional HPV Types,” March 2, 2015, 
http://www.cancer.gov/clinicaltrials/results/summary/2015/gardasil9-0215. 
82 Larson, Brocard, and Garnett, “The India HPV-Vaccine Suspension,” 572–73. 
83 Department-Related Parliamentary Standing Committee on Health And Family Welfare, “Seventy Second 
Report Alleged Irregularities in the Conduct of Studies Using Human Papilloma Virus (HPV) Vaccine by Path in 
India,” Parliament of India Rajya Sabha, August 30, 2013, http://164.100.47.5/newcommittee/reports/ 
EnglishCommittees/Committee%20on%20Health%20and%20Family%20Welfare/72.pdf and 
https://www.pharmamedtechbi.com/~/media/Supporting%20Documents/Pharmasia%20News/2013/September/H
PV%20Vaccines%20Parliameetnary%20Report%20%20Aug%2031%202013.pdf. 
84 “Supreme Court asks Centre to respond on clinical trial of vaccines,” The Economic Times, January 13, 2015, 
http://articles.economictimes.indiatimes.com/2015-01-13/news/58024587_1_gardasil-and-cervarix-vaccines-
justices-dipak-misra. 
85 Teena Thacker, “Government orders HPV vaccine study,” The Asian Age, February 25, 2015, 
http://www.asianage.com/india/government-orders-hpv-vaccine-study-751. 
86 “Court glare on ‘harmful, costly’ vaccines—Rs 15 or Rs 525? Notices to govt after petitions allege favour to 
private players,” The Telegraph India, September 2, 2013, http://www.telegraphindia.com/1130903/ 
jsp/nation/story_17305212.jsp#.VR0sifnF98F. 
87 Thacker, “Government orders HPV vaccine study.” 
88 World Health Organization, “Case Study C: How a Potential HPV Vaccination Crisis Was Averted,” 
http://vaccine-safety-training.org/c-resources.html. 
89 James Meikle, “HPV vaccine could be given to boys as well as girls in UK,” The Guardian, November 28, 2013, 
http://www.theguardian.com/society/2013/nov/28/hpv-vaccine-boys-girls-cancer-uk. 
90 “HPV vaccine: should boys get it too?,” The Telegraph (London), March 12, 2015, 
http://www.telegraph.co.uk/men/active/mens-health/11467138/HPV-vaccine-should-boys-get-it-too.html. 
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advisable to vaccinate men who have sex with men,91 and the population-wide vaccination 
of boys has been subsequently postponed until 2017.92, 93, 94 This postponement has sparked 
increased discussion in the local media, with an emphasis on criticizing government 
officials on budgeting and votes.95, 96 
Australia 
In Australia, positive and transparent information about the HPV vaccine was strengthened 
following adverse events experienced by several dozen Melbourne schoolgirls. The state 
government established a new service, Surveillance of Adverse Events Following 
Vaccination in the Community (SAEFVIC) in April 200754 and the vaccine was not 
suspended. On September 2, 2014, Harrison et al. published that the large decrease in 
genital warts in Australian women of vaccine-eligible age highlights the success of the 
National HPV Vaccination program.97 The publication received wide media attention both 
within Australia and globally.98, 99, 100 A separate paper by M. A. Smith of the Cancer 
Screening Group cited trends in HPV vaccination in Australia, concluding that “Australia 
has implemented a successful and equitable vaccination program against HPV.”101 
In response to the successful vaccination program, there have been reports that Australia is 
planning to shift to primary HPV testing from Pap tests next year, as mentioned by Karen 
Canfell, chairman of Cancer Council Australia’s Cancer Screening Committee.97 
91 Laura Donnelly, “Gay men to be offered HPV jab under new guidelines,” The Telegraph (London), November 
12, 2014, http://www.telegraph.co.uk/news/health/news/11226126/Gay-men-to-be-offered-HPV-jab-under-new-
guildelines-to-Government.html. 
92 Joint Committee on Vaccination and Immunisation, “Minute of the meeting on 4 February 2015,” 
https://app.box.com/ s/iddfb4ppwkmtjusir2tc/1/2199012147/27417264008/1. 
93 “UK postpones HPV vaccine for males,” Washington Blade, March 20, 2015, http://www.washingtonblade.com/ 
2015/03/20/uk-postpones-hpv-vaccine-for-males/. 
94 UK Parliament, “Human Papillomavirus: Vaccination: Written question—225307: To ask the Secretary of State 
for Health, when he expects his Department to be in a position to make a decision on HPV vaccination for 
adolescent boys,” March 4, 2015, http://www.parliament.uk/business/publications/written-questions-answers-
statements/written-question/Commons/2015-02-25/225307. 
95 Nick Duffy, “Department of Health ‘awaiting advice’ on extending HPV vaccine to gay men,” Pink News, March 
13 2015, http://www.pinknews.co.uk/2015/03/13/department-of-health-awaiting-advice-on-extending-hpv-
vaccine-to-gay-men/. 
96 Gillian Prue, “Why boys should get the HPV vaccine too,” The Conversation, February 9, 2015, 
http://theconversation.com/why-boys-should-get-the-hpv-vaccine-too-36932. 
97 Christopher Harrison et al., “Decreased Management of Genital Warts in Young Women in Australian General 
Practice Post Introduction of National HPV Vaccination Program: Results from a Nationally Representative 
Cross-Sectional General Practice Study,” PLoS One 9, no. 9 (2014): e105967, http://journals.plos.org/plosone/ 
article?id=10.1371/journal.pone.0105967. 
98 German Lopez, “Australia’s free HPV vaccine program is a big success,” Vox, September 8, 2014, 
http://www.vox.com/2014/9/8/6122575/hpv-vaccine-australia-success. 
99 Simon Santow, “Vaccination success against HPV,” ABC News, August 13, 2014, http://www.abc.net.au/pm/ 
content/2014/s4066535.htm. 
100 Megan Howe, “Witnessing protection via the human papillomavirus vaccine,” The Saturday Paper, February 
28, 2015, http://www.thesaturdaypaper.com.au/2015/02/28/witnessing-protection-via-the-human-papillomavirus-
vaccine/14250420001530#.VSP5_fzF-So. 
101 Cancer Council Australia, “Has the program been successful?,” http://www.hpvvaccine.org.au/the-hpv-
vaccine/has-the-program-been-successful.aspx. 
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 Rwanda 
A comprehensive national education campaign preceded nationwide implementation of a 
school-based HPV vaccination program in Rwanda in 2011.102 Despite public concerns 
surrounding the introduction of a new vaccine,103 Rwanda has achieved coverage of more 
than 90 percent for girls by enlisting health professionals, religious leaders, prominent 
politicians, and teachers as advocates from the very beginning. This demonstrates that with 
sufficient planning and an active policy of engagement prior to implementation, high 
coverage can be achieved despite low knowledge of HPV-related diseases and vaccines.104  
Tanzania 
The HPV vaccine is currently only available from demonstration projects in Tanzania.105 
While knowledge of HPV-related diseases and the vaccine is low in rural areas and there 
was concern among parents about the vaccine’s effect on fertility 106, 107—an issue that may 
have stemmed from rumors surrounding the tetanus toxoid vaccination previously108—
vaccine acceptance is high at 93 percent. Information is mostly provided by clinicians 
(deemed trustworthy by the population), popular media sources, and community-based 
routes such as churches. 
See Appendix 1 for a summary of country concerns and Appendix 2 for a timeline 
illustrating when these events occurred. 
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Appendix 1: Summary of Country Case Studies  
Country Date of 
licensing  
Date of NIP 
inclusion  
Date and prompters of vaccine 
concerns  
When and what was the 
government response?  
Australia April 2007  April 2007  May 2007: 720 girls receive HPV 
vaccination at Melbourne girl’s 
school. 26 girls develop symptoms 
including dizziness, syncope, and 
neurological complaints. 4 taken to 
hospital. 
2016: plan to shift to primary HPV 
testing from Pap tests in response 
to successful vaccination program.  
Radio interviews with then-
federal health minister and 
Victorian state premier. State 
government funded new service, 
SAEFVIC (Surveillance of Adverse 
Events Following Vaccination in 
the Community) in April 2007. No 
vaccine suspension. 
Colombia December 
2006 
September 
2012 
August 2014: 243 cases of cold feet, 
malaise, headache, weight loss, 
numbness, fainting, paralysis, and 
seizures 
President, government, and 
Ministry of Health stood by their 
confidence in vaccine’s safety 
and efficacy. No vaccine 
suspension.  
Denmark 2006 2009 March 2015: TV program about 
vaccinated girls having chronic 
headaches, muscle aches, and 
muscle failure. 
Danish Health and Medicines 
Authority (DHMA) 
pharmacovigilance reports 
referring to suspected adverse 
events in May 2014 and 
September 2014. No vaccine 
suspension. 
New 
Zealand 
July 2006 September 
2008 
March 2015: PhD student report of 
low vaccination coverage among 
population in “other” category and 
suggests hypothesis of “white girls 
don’t have sex theory” as reason. 
Family First NZ uses difference in 
coverage with ethnicity to support 
notion that “contrary 
to claims that ‘well-off Pakeha 
girls’ are rejecting the HPV 
vaccine, parents of all racial 
groups in New Zealand are rightly 
rejecting the pressure to have their 
children vaccinated for an 
infection which isn’t a 
communicable disease but a 
consequence of behaviour.” 
No official government response. 
No vaccine suspension. 
 Japan October 
2009 
April 2013  April 2013: Family of allegedly 
affected girl compensated by 
Suginami local government 
31 March 2015: Anti-vaccination 
groups protest outside MSD and 
GSK 
26 April 2015: National Cervical 
Cancer Vaccine Victim Liaison 
Committee announces plans for 
national “Vaccine Talk 2015” event 
June 14, 2013: Government 
suspends HPV vaccination 
recommendation. 
January 2015: Ministry of Health, 
Labour, and Welfare (MHLW) 
panel of experts rules out 
possibility that adverse events 
after HPV vaccination were 
caused by immunological or 
neurological effects of vaccine, 
but recommendation for HPV 
vaccination was not reinstated. 
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 India 
 
July 2008 Not yet 
included 
October 2009: Public criticism of 
HPV vaccine demonstration 
project, vaccine safety concerns, 
costs, and ethical concerns. 
April 2010: Press conference and 
memorandum to health minister 
highlighting previous concerns 
and four deaths associated 
temporally with HPV vaccination. 
Public interest litigation initiated. 
April 2010: Government suspends 
HPV vaccination demonstration 
project. 
Ongoing parliamentary inquiry 
and Supreme Court hearings. 
Early 2015: National 
Immunization Technical 
Advisory Group invited to 
evaluate safety and efficacy of 
HPV vaccine. 
United 
Kingdom 
June 2006 September 
2008 
September 28, 2009: Young girl in 
Coventry collapses and dies soon 
after first dose of HPV vaccine 
Evening of September 28, 2009: 
UK Department of Health acts 
quickly to inform media and 
public that death was not due to 
HPV vaccine. No vaccine 
suspension. 
France July 2007 October 2007 March 28, 2014 (to nine-year-olds).  
July 10, 2014 (push for further 
vaccination coverage): Henri 
Joyeux’s makes cautionary 
statement and launches petition 
against school HPV vaccination 
with IPSN on September 15, 2014. 
No new government response. 
No vaccine suspension. 
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Appendix 2. Timeline of Safety Concerns 
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